-
Eli Lilly China President and General Manager Declan: Obese patients should have access to multiple treatment options
At present, there is still a certain degree of discrimination against overweight people, especially obese patients, in society. This leads them to believe that obesity is their own fault and personal ... -
The Battle of Weight Loss Drugs Begins: Smegglutide's Obesity Indications Approved in China
Recently, there has been new news in the field of GLP-1 (glucagon like peptide-1) weight loss. Novo Nordisk announced that the National Medical Products Administration (NMPA) has approved the marketi ... -
Lilly plans to launch the obesity drug Telposide in India as early as next year
On February 28th, Eli Lilly CEO Dai Wenrui stated in an interview that the company expects to launch the obesity drug Tirzepatide in India as early as next year. During his keynote speech at the BioA ... -
Not only the miracle medicine for weight loss! Novo Nordisk's search for the development of "obesity prevention drugs" is still in its early stages of research
While pharmaceutical giants are still fiercely competing over GLP-1 weight loss drugs, Danish pharmaceutical giant Novo Nordisk has already set its sights on developing drugs to prevent obesity. -
Novo Nordisk seeks to develop obesity prevention drugs
On December 5th, Novo Nordisk is conducting experiments and research to understand the causes of obesity and seeking to develop drugs to prevent obesity.